Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

2019 Annual Meeting of Stockholders

Jul 23, 2019 • 10:00am EDT